Color-coding cancer and stromal cells with genetic reporters in a patient-derived orthotopic xenograft (PDOX) model of pancreatic cancer enhances fluorescence-guided surgery

Shuuya Yano; Y. Hiroshima; A. Maawy; Hiroyuki Kishimoto; A. Suetsugu; S. Miwa; M. Toneri; M. Yamamoto; M. H.G. Katz; J. B. Fleming; Y. Urata; H. Tazawa; S. Kagawa; M. Bouvet; T. Fujiwara; R. M. Hoffman

doi:10.1038/cgt.2015.26

Color-coding cancer and stromal cells with genetic reporters in a patient-derived orthotopic xenograft (PDOX) model of pancreatic cancer enhances fluorescence-guided surgery

Shuuya Yano, Y. Hiroshima, A. Maawy, Hiroyuki Kishimoto, A. Suetsugu, S. Miwa, M. Toneri, M. Yamamoto, M. H.G. Katz, J. B. Fleming, Y. Urata, H. Tazawa, S. Kagawa, M. Bouvet, T. Fujiwara, R. M. Hoffman

研究成果 › 査読

45 被引用数 (Scopus)

抄録

Precise fluorescence-guided surgery (FGS) for pancreatic cancer has the potential to greatly improve the outcome in this recalcitrant disease. To achieve this goal, we have used genetic reporters to color code cancer and stroma cells in a patient-derived orthotopic xenograft (PDOX) model. The telomerase-dependent green fluorescent protein (GFP)-containing adenovirus OBP-401 was used to label the cancer cells of a pancreatic cancer PDOX. The PDOX was previously grown in a red fluorescent protein (RFP) transgenic mouse that stably labeled the PDOX stroma cells bright red. The color-coded PDOX model enabled FGS to completely resect the pancreatic tumors including stroma. Dual-colored FGS significantly prevented local recurrence, which bright-light surgery or single-color FGS could not. FGS, with color-coded cancer and stroma cells has important potential for improving the outcome of recalcitrant-cancer surgery.

本文言語	English
ページ（範囲）	344-350
ページ数	7
ジャーナル	Cancer Gene Therapy
巻	22
号	7
DOI	https://doi.org/10.1038/cgt.2015.26
出版ステータス	Published - 7月 25 2015

ASJC Scopus subject areas

分子医療
分子生物学
癌研究

UN SDG

この成果は、次の持続可能な開発目標に貢献しています

文献へのアクセス

10.1038/cgt.2015.26

他のファイルとリンク

フィンガープリント

「Color-coding cancer and stromal cells with genetic reporters in a patient-derived orthotopic xenograft (PDOX) model of pancreatic cancer enhances fluorescence-guided surgery」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル

Yano, S., Hiroshima, Y., Maawy, A., Kishimoto, H., Suetsugu, A., Miwa, S., Toneri, M., Yamamoto, M., Katz, M. H. G., Fleming, J. B., Urata, Y., Tazawa, H., Kagawa, S., Bouvet, M., Fujiwara, T., & Hoffman, R. M. (2015). Color-coding cancer and stromal cells with genetic reporters in a patient-derived orthotopic xenograft (PDOX) model of pancreatic cancer enhances fluorescence-guided surgery. Cancer Gene Therapy, 22(7), 344-350. https://doi.org/10.1038/cgt.2015.26

Yano, S, Hiroshima, Y, Maawy, A, Kishimoto, H, Suetsugu, A, Miwa, S, Toneri, M, Yamamoto, M, Katz, MHG, Fleming, JB, Urata, Y, Tazawa, H , Kagawa, S, Bouvet, M, Fujiwara, T & Hoffman, RM 2015, 'Color-coding cancer and stromal cells with genetic reporters in a patient-derived orthotopic xenograft (PDOX) model of pancreatic cancer enhances fluorescence-guided surgery', Cancer Gene Therapy, vol. 22, no. 7, pp. 344-350. https://doi.org/10.1038/cgt.2015.26

@article{3b8f1f843ee74a7596ed11e3653adf1d,

title = "Color-coding cancer and stromal cells with genetic reporters in a patient-derived orthotopic xenograft (PDOX) model of pancreatic cancer enhances fluorescence-guided surgery",

abstract = "Precise fluorescence-guided surgery (FGS) for pancreatic cancer has the potential to greatly improve the outcome in this recalcitrant disease. To achieve this goal, we have used genetic reporters to color code cancer and stroma cells in a patient-derived orthotopic xenograft (PDOX) model. The telomerase-dependent green fluorescent protein (GFP)-containing adenovirus OBP-401 was used to label the cancer cells of a pancreatic cancer PDOX. The PDOX was previously grown in a red fluorescent protein (RFP) transgenic mouse that stably labeled the PDOX stroma cells bright red. The color-coded PDOX model enabled FGS to completely resect the pancreatic tumors including stroma. Dual-colored FGS significantly prevented local recurrence, which bright-light surgery or single-color FGS could not. FGS, with color-coded cancer and stroma cells has important potential for improving the outcome of recalcitrant-cancer surgery.",

author = "Shuuya Yano and Y. Hiroshima and A. Maawy and Hiroyuki Kishimoto and A. Suetsugu and S. Miwa and M. Toneri and M. Yamamoto and Katz, {M. H.G.} and Fleming, {J. B.} and Y. Urata and H. Tazawa and S. Kagawa and M. Bouvet and T. Fujiwara and Hoffman, {R. M.}",

note = "Funding Information: This study was supported in part by the National Cancer Institute grant CA132971 and CA142669. This study was also supported in part by grants-in-Aid from the Ministry of Education, Science and Culture, Japan, and grants from the Ministry of Health and Welfare, Japan. Publisher Copyright: {\textcopyright} 2015 Nature America, Inc. All rights reserved.",

year = "2015",

month = jul,

day = "25",

doi = "10.1038/cgt.2015.26",

language = "English",

volume = "22",

pages = "344--350",

journal = "Cancer Gene Therapy",

issn = "0929-1903",

publisher = "Nature Publishing Group",

number = "7",

}

TY - JOUR

T1 - Color-coding cancer and stromal cells with genetic reporters in a patient-derived orthotopic xenograft (PDOX) model of pancreatic cancer enhances fluorescence-guided surgery

AU - Yano, Shuuya

AU - Hiroshima, Y.

AU - Maawy, A.

AU - Kishimoto, Hiroyuki

AU - Suetsugu, A.

AU - Miwa, S.

AU - Toneri, M.

AU - Yamamoto, M.

AU - Katz, M. H.G.

AU - Fleming, J. B.

AU - Urata, Y.

AU - Tazawa, H.

AU - Kagawa, S.

AU - Bouvet, M.

AU - Fujiwara, T.

AU - Hoffman, R. M.

N1 - Funding Information: This study was supported in part by the National Cancer Institute grant CA132971 and CA142669. This study was also supported in part by grants-in-Aid from the Ministry of Education, Science and Culture, Japan, and grants from the Ministry of Health and Welfare, Japan. Publisher Copyright: © 2015 Nature America, Inc. All rights reserved.

PY - 2015/7/25

Y1 - 2015/7/25

N2 - Precise fluorescence-guided surgery (FGS) for pancreatic cancer has the potential to greatly improve the outcome in this recalcitrant disease. To achieve this goal, we have used genetic reporters to color code cancer and stroma cells in a patient-derived orthotopic xenograft (PDOX) model. The telomerase-dependent green fluorescent protein (GFP)-containing adenovirus OBP-401 was used to label the cancer cells of a pancreatic cancer PDOX. The PDOX was previously grown in a red fluorescent protein (RFP) transgenic mouse that stably labeled the PDOX stroma cells bright red. The color-coded PDOX model enabled FGS to completely resect the pancreatic tumors including stroma. Dual-colored FGS significantly prevented local recurrence, which bright-light surgery or single-color FGS could not. FGS, with color-coded cancer and stroma cells has important potential for improving the outcome of recalcitrant-cancer surgery.

AB - Precise fluorescence-guided surgery (FGS) for pancreatic cancer has the potential to greatly improve the outcome in this recalcitrant disease. To achieve this goal, we have used genetic reporters to color code cancer and stroma cells in a patient-derived orthotopic xenograft (PDOX) model. The telomerase-dependent green fluorescent protein (GFP)-containing adenovirus OBP-401 was used to label the cancer cells of a pancreatic cancer PDOX. The PDOX was previously grown in a red fluorescent protein (RFP) transgenic mouse that stably labeled the PDOX stroma cells bright red. The color-coded PDOX model enabled FGS to completely resect the pancreatic tumors including stroma. Dual-colored FGS significantly prevented local recurrence, which bright-light surgery or single-color FGS could not. FGS, with color-coded cancer and stroma cells has important potential for improving the outcome of recalcitrant-cancer surgery.

UR - http://www.scopus.com/inward/record.url?scp=84937978947&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937978947&partnerID=8YFLogxK

U2 - 10.1038/cgt.2015.26

DO - 10.1038/cgt.2015.26

M3 - Article

C2 - 26088297

AN - SCOPUS:84937978947

SN - 0929-1903

VL - 22

SP - 344

EP - 350

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

IS - 7

ER -